Ruxolitinib to Combat COVID-19

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

December 31, 2021

Conditions
COVID-19
Interventions
DRUG

Ruxolitinib

For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube

PROCEDURE

Peripheral blood draw

-Screening, Day 2, Day 4, Day 8, Day 15, and Day 29

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT04354714 - Ruxolitinib to Combat COVID-19 | Biotech Hunter | Biotech Hunter